Lord, Abbett & Co. LLC Prometheus Biosciences, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 07, 2024	BUY	$103.46 - $126.29 $14.1 Million - $17.2 Million	136,040 Added 44.89%	439,098 $47.1 Million
Q1 2023 May 12, 2023	BUY	$103.46 - $126.29 $14.1 Million - $17.2 Million	136,040 Added 44.89%	439,098 $47.1 Million
Q4 2022 Oct 07, 2024	BUY	$36.06 - $117.21 $10.9 Million - $35.5 Million	303,058 New	303,058 $33.3 Million
Q4 2022 Feb 10, 2023	BUY	$36.06 - $117.21 $10.9 Million - $35.5 Million	303,058 New	303,058 $33.3 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.